215 related articles for article (PubMed ID: 27622064)
1. Loss of DNAM-1 ligand expression by acute myeloid leukemia cells renders them resistant to NK cell killing.
Kearney CJ; Ramsbottom KM; Voskoboinik I; Darcy PK; Oliaro J
Oncoimmunology; 2016 Aug; 5(8):e1196308. PubMed ID: 27622064
[TBL] [Abstract][Full Text] [Related]
2. Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients.
Sanchez-Correa B; Gayoso I; Bergua JM; Casado JG; Morgado S; Solana R; Tarazona R
Immunol Cell Biol; 2012 Jan; 90(1):109-15. PubMed ID: 21383766
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint molecule DNAM-1/CD112 axis is a novel target for natural killer-cell therapy in acute myeloid leukemia.
Kaito Y; Sugimoto E; Nakamura F; Tsukune Y; Sasaki M; Yui S; Yamaguchi H; Goyama S; Nannya Y; Mitani K; Tamura H; Imai Y
Haematologica; 2024 Apr; 109(4):1107-1120. PubMed ID: 37731380
[TBL] [Abstract][Full Text] [Related]
4. CD155 and CD112 as possible therapeutic targets of
Kaito Y; Hirano M; Futami M; Nojima M; Tamura H; Tojo A; Imai Y
Oncol Lett; 2022 Feb; 23(2):51. PubMed ID: 34992684
[TBL] [Abstract][Full Text] [Related]
5. DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy.
Sanchez-Correa B; Valhondo I; Hassouneh F; Lopez-Sejas N; Pera A; Bergua JM; Arcos MJ; Bañas H; Casas-Avilés I; Durán E; Alonso C; Solana R; Tarazona R
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31234588
[TBL] [Abstract][Full Text] [Related]
6. Increased CD112 expression in methylcholanthrene-induced tumors in CD155-deficient mice.
Nagumo Y; Iguchi-Manaka A; Yamashita-Kanemaru Y; Abe F; Bernhardt G; Shibuya A; Shibuya K
PLoS One; 2014; 9(11):e112415. PubMed ID: 25384044
[TBL] [Abstract][Full Text] [Related]
7. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells.
El-Sherbiny YM; Meade JL; Holmes TD; McGonagle D; Mackie SL; Morgan AW; Cook G; Feyler S; Richards SJ; Davies FE; Morgan GJ; Cook GP
Cancer Res; 2007 Sep; 67(18):8444-9. PubMed ID: 17875681
[TBL] [Abstract][Full Text] [Related]
8. CD155 blockade enhances allogeneic natural killer cell-mediated antitumor response against osteosarcoma.
Cho MM; Song L; Quamine AE; Szewc F; Shi L; Erbe AK; Ebben JD; Turicek DP; Kline JM; Lafeber EO; Phillips MF; Ceas AS; Capitini CM
bioRxiv; 2024 Jan; ():. PubMed ID: 37333207
[TBL] [Abstract][Full Text] [Related]
9. Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy.
Mastaglio S; Wong E; Perera T; Ripley J; Blombery P; Smyth MJ; Koldej R; Ritchie D
Blood Adv; 2018 Feb; 2(4):335-346. PubMed ID: 29449224
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the DNAM-1, TIGIT and TACTILE Axis on Circulating NK, NKT-Like and T Cell Subsets in Patients with Acute Myeloid Leukemia.
Valhondo I; Hassouneh F; Lopez-Sejas N; Pera A; Sanchez-Correa B; Guerrero B; Bergua JM; Arcos MJ; Bañas H; Casas-Avilés I; Sanchez-Garcia J; Serrano J; Martin C; Duran E; Alonso C; Solana R; Tarazona R
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32764229
[No Abstract] [Full Text] [Related]
11. DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases.
Chan CJ; Andrews DM; McLaughlin NM; Yagita H; Gilfillan S; Colonna M; Smyth MJ
J Immunol; 2010 Jan; 184(2):902-11. PubMed ID: 20008292
[TBL] [Abstract][Full Text] [Related]
12. Acute myeloid leukemia impairs natural killer cells through the formation of a deficient cytotoxic immunological synapse.
Khaznadar Z; Henry G; Setterblad N; Agaugue S; Raffoux E; Boissel N; Dombret H; Toubert A; Dulphy N
Eur J Immunol; 2014 Oct; 44(10):3068-80. PubMed ID: 25041786
[TBL] [Abstract][Full Text] [Related]
13. CD155/PVR determines acute myeloid leukemia targeting by Delta One T cells.
Mensurado S; Condeço C; Sánchez-Martínez D; Shirley S; Coelho RML; Tirado N; Vinyoles M; Blanco-Domínguez R; Barros L; Galvão B; Custódio N; Gomes da Silva M; Menéndez P; Silva-Santos B
Blood; 2024 Apr; 143(15):1488-1495. PubMed ID: 38437507
[TBL] [Abstract][Full Text] [Related]
14. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112).
Tahara-Hanaoka S; Shibuya K; Onoda Y; Zhang H; Yamazaki S; Miyamoto A; Honda S; Lanier LL; Shibuya A
Int Immunol; 2004 Apr; 16(4):533-8. PubMed ID: 15039383
[TBL] [Abstract][Full Text] [Related]
15. CD155 on HIV-Infected Cells Is Not Modulated by HIV-1 Vpu and Nef but Synergizes with NKG2D Ligands to Trigger NK Cell Lysis of Autologous Primary HIV-Infected Cells.
Davis ZB; Sowrirajan B; Cogswell A; Ward JP; Planelles V; Barker E
AIDS Res Hum Retroviruses; 2017 Feb; 33(2):93-100. PubMed ID: 27296670
[TBL] [Abstract][Full Text] [Related]
16. DNAM-1/CD226 is functionally expressed on acute myeloid leukemia (AML) cells and is associated with favorable prognosis.
Chashchina A; Märklin M; Hinterleitner C; Salih HR; Heitmann JS; Klimovich B
Sci Rep; 2021 Sep; 11(1):18012. PubMed ID: 34504191
[TBL] [Abstract][Full Text] [Related]
17. The Role of T Cell Costimulation via DNAM-1 in Kidney Transplantation.
Kraus AK; Chen J; Edenhofer I; Ravens I; Gaspert A; Cippà PE; Mueller S; Wuthrich RP; Segerer S; Bernhardt G; Fehr T
PLoS One; 2016; 11(2):e0147951. PubMed ID: 26840537
[TBL] [Abstract][Full Text] [Related]
18. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule.
Bottino C; Castriconi R; Pende D; Rivera P; Nanni M; Carnemolla B; Cantoni C; Grassi J; Marcenaro S; Reymond N; Vitale M; Moretta L; Lopez M; Moretta A
J Exp Med; 2003 Aug; 198(4):557-67. PubMed ID: 12913096
[TBL] [Abstract][Full Text] [Related]
19. Identification and functional analysis of ligands for natural killer cell activating receptors in colon carcinoma.
Zhang Z; Su T; He L; Wang H; Ji G; Liu X; Zhang Y; Dong G
Tohoku J Exp Med; 2012 Jan; 226(1):59-68. PubMed ID: 22189020
[TBL] [Abstract][Full Text] [Related]
20. Human Induced Pluripotent Stem Cells Are Targets for Allogeneic and Autologous Natural Killer (NK) Cells and Killing Is Partly Mediated by the Activating NK Receptor DNAM-1.
Kruse V; Hamann C; Monecke S; Cyganek L; Elsner L; Hübscher D; Walter L; Streckfuss-Bömeke K; Guan K; Dressel R
PLoS One; 2015; 10(5):e0125544. PubMed ID: 25950680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
